Editas Medicine Shares Jump on Narrower 4Q Loss, Revenue Beat

Dow Jones03-09

By Amira McKee

Shares of Editas Medicine climbed after the company logged a narrower fourth-quarter loss and revenue that outperformed analyst estimates.

The stock jumped 16% to $2.32 in Monday morning trading. The shares have gained 35% in the past year.

The developer of genome editing technology recorded a fourth-quarter loss of $5.6 million, or six cents a share, compared with a loss of $45.4 million, or 55 cents a share, a year earlier.

The results beat Wall Street's forecast for a fourth-quarter loss of 27 cents a share, according to FactSet.

Revenue was $24.7 million, down from $30.6 million a year prior, but exceeding the $8.3 million that analysts polled by FactSet were expecting.

The company attributed the top-line decline to milestone payments that boosted revenue in the fourth quarter of 2024.

Research and development expenses and general administrative expenses declined by 44% and 30%, respectively. Restructuring and impairment charges swung from $12.2 million to a benefit of $6.3 million. The decline in expenses was primarily driven by the discontinuation of clinical development of the company's reni-cel program and a workforce reduction.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

March 09, 2026 10:55 ET (14:55 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618276586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618276586","market":"hk","top_or_hot":-1,"title":"Editas Medicine Shares Jump on Narrower 4Q Loss, Revenue Beat","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> climbed after the company logged a narrower fourth-quarter loss and revenue that outperformed analyst estimates. \n</p>\n<p>\n  The stock jumped 16% to $2.32 in Monday morning trading. The shares have gained 35% in the past year. \n</p>\n<p>\n  The developer of genome editing technology recorded a fourth-quarter loss of $5.6 million, or six cents a share, compared with a loss of $45.4 million, or 55 cents a share, a year earlier. \n</p>\n<p>\n  The results beat Wall Street's forecast for a fourth-quarter loss of 27 cents a share, according to FactSet. \n</p>\n<p>\n  Revenue was $24.7 million, down from $30.6 million a year prior, but exceeding the $8.3 million that analysts polled by FactSet were expecting. \n</p>\n<p>\n  The company attributed the top-line decline to milestone payments that boosted revenue in the fourth quarter of 2024. \n</p>\n<p>\n  Research and development expenses and general administrative expenses declined by 44% and 30%, respectively. Restructuring and impairment charges swung from $12.2 million to a benefit of $6.3 million. The decline in expenses was primarily driven by the discontinuation of clinical development of the company's reni-cel program and a workforce reduction. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 10:55 ET (14:55 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Editas Medicine Shares Jump on Narrower 4Q Loss, Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEditas Medicine Shares Jump on Narrower 4Q Loss, Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-09 22:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> climbed after the company logged a narrower fourth-quarter loss and revenue that outperformed analyst estimates. \n</p>\n<p>\n  The stock jumped 16% to $2.32 in Monday morning trading. The shares have gained 35% in the past year. \n</p>\n<p>\n  The developer of genome editing technology recorded a fourth-quarter loss of $5.6 million, or six cents a share, compared with a loss of $45.4 million, or 55 cents a share, a year earlier. \n</p>\n<p>\n  The results beat Wall Street's forecast for a fourth-quarter loss of 27 cents a share, according to FactSet. \n</p>\n<p>\n  Revenue was $24.7 million, down from $30.6 million a year prior, but exceeding the $8.3 million that analysts polled by FactSet were expecting. \n</p>\n<p>\n  The company attributed the top-line decline to milestone payments that boosted revenue in the fourth quarter of 2024. \n</p>\n<p>\n  Research and development expenses and general administrative expenses declined by 44% and 30%, respectively. Restructuring and impairment charges swung from $12.2 million to a benefit of $6.3 million. The decline in expenses was primarily driven by the discontinuation of clinical development of the company's reni-cel program and a workforce reduction. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 10:55 ET (14:55 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EDIT","symbol_name":"Editas Medicine, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618276586","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618276586","pubTimestamp":1773068100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Editas Medicine climbed after the company logged a narrower fourth-quarter loss and revenue that outperformed analyst estimates.The stock jumped 16% to $2.32 in Monday morning trading. The shares have gained 35% in the past year.The developer of genome editing technology recorded a fourth-quarter loss of $5.6 million, or six cents a share, compared with a loss of $45.4 million, or 55 cents a share, a year earlier.The results beat Wall Street's forecast for a fourth-quarter loss of 27 cents a share, according to FactSet.Revenue was $24.7 million, down from $30.6 million a year prior, but exceeding the $8.3 million that analysts polled by FactSet were expecting.The company attributed the top-line decline to milestone payments that boosted revenue in the fourth quarter of 2024.Research and development expenses and general administrative expenses declined by 44% and 30%, respectively. Restructuring and impairment charges swung from $12.2 million to a benefit of $6.3 million. The ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EDIT":"Editas Medicine, Inc."},"translate_title":"Editas Medicine股价因第四季度亏损收窄和收入超出预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDIT":1.5},"content_text":"By Amira McKee \n\n\n \n\n\n  Shares of Editas Medicine climbed after the company logged a narrower fourth-quarter loss and revenue that outperformed analyst estimates. \n\n\n  The stock jumped 16% to $2.32 in Monday morning trading. The shares have gained 35% in the past year. \n\n\n  The developer of genome editing technology recorded a fourth-quarter loss of $5.6 million, or six cents a share, compared with a loss of $45.4 million, or 55 cents a share, a year earlier. \n\n\n  The results beat Wall Street's forecast for a fourth-quarter loss of 27 cents a share, according to FactSet. \n\n\n  Revenue was $24.7 million, down from $30.6 million a year prior, but exceeding the $8.3 million that analysts polled by FactSet were expecting. \n\n\n  The company attributed the top-line decline to milestone payments that boosted revenue in the fourth quarter of 2024. \n\n\n  Research and development expenses and general administrative expenses declined by 44% and 30%, respectively. Restructuring and impairment charges swung from $12.2 million to a benefit of $6.3 million. The decline in expenses was primarily driven by the discontinuation of clinical development of the company's reni-cel program and a workforce reduction. \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 10:55 ET (14:55 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618276586","isCrawlerRequest":true}